HOUSTON, Sept. 8,
2022 /PRNewswire/ -- Moleculin Biotech, Inc.,
(Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical
stage pharmaceutical company with a broad portfolio of drug
candidates targeting highly resistant tumors and viruses, today
announced that members of management will virtually present at the
2nd Annual Marie Sklodowska-Curie Symposium on Cancer
Research and Care being held at the Roswell Park Comprehensive
Cancer Center in Buffalo, NY
September 8-10, 2022.
Details of the presentations are as follows:
Title: The Value of Collaboration in Clinical
Development: Experience from Poland
Presenter: Walter
Klemp, President and Chief Executive Officer
Session 2: Opportunities for International Collaborations
& Funding
Date & Time: Friday, September
9 at 12:05 PM ET
Title: Translating Preclinical Research Into Clinical
Trials
Presenter: Robert
Shepard, MD, FACP, Medical Advisor
Session B: Translational Research
Date &
Time: Saturday, September 10 at
11:10 AM ET
For more information about the conference, visit:
www.roswellpark.org/msc-symposium.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of drug
candidates for the treatment of highly resistant tumors and
viruses. The Company's lead program, Annamycin, is a
next-generation anthracycline designed to avoid multidrug
resistance mechanisms with little to no cardiotoxicity. Annamycin
is currently in development for the treatment of relapsed or
refractory acute myeloid leukemia (AML) and soft tissue sarcoma
(STS) lung metastases.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator designed to be capable of inhibiting
p-STAT3 and other oncogenic transcription factors while also
stimulating a natural immune response, targeting brain tumors,
pancreatic and other cancers; and WP1220, an analog to WP1066, for
the topical treatment of cutaneous T-cell lymphoma. Moleculin is
also engaged in the development of a portfolio of antimetabolites,
including WP1122, for the potential treatment of COVID-19 and other
viruses, as well as cancer indications including brain tumors,
pancreatic and other cancers.
For more information about the Company, please visit
www.moleculin.com and connect on Twitter, LinkedIn and
Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, whether the results of
Moleculin's preclinical models can be replicated in human trials,
Moleculin's ability to conduct a potential future Phase 2 COVID-19
clinical study, Moleculin's ability to identify and attract
collaborators for additional clinical trials of WP1122, and the
ability for WP1122 to be shown safe and effective in humans.
Although Moleculin believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Moleculin has attempted to identify forward-looking statements by
terminology including 'believes,' 'estimates,' 'anticipates,'
'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,'
'could,' 'might,' 'will,' 'should,' 'approximately' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under Item 1A. "Risk
Factors" in our most recently filed Form 10-K filed with the
Securities and Exchange Commission ("SEC") and updated from time to
time in our Form 10-Q filings and in our other public filings with
the SEC. Any forward-looking statements contained in this release
speak only as of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-selected-to-present-at-the-2nd-annual-marie-sklodowska-curie-symposium-on-cancer-research-and-care-301620215.html
SOURCE Moleculin Biotech, Inc.